A recent study published in The Lancet found that gepotidacin, a new antibiotic, is as effective as the current standard treatment for drug-resistant gonorrhea. The clinical trial demonstrated that gepotidacin cured 92.6% of participants, matching the success rate of the conventional regimen. Experts believe that the new oral therapy could be the first new treatment for gonorrhea in over 30 years and may help slow down drug resistance. However, more research is needed to understand the efficacy of gepotidacin in different populations and potential bacterial resistance.